Abiopharma

🔍 FRIEDMAN PAUL A (Director)

Company: MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 280 shares of Common Stock at $15.8 per share (Direct)
  Date: 2026-01-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 187,444.00 | transaction_form_type: 4
• Sold 280 shares of Common Stock at $551.2414 per share (Direct)
  Date: 2026-01-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 187,164.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-09 | Code: H | nature_of_ownership: By SQN LLC | shares_owned_after: 655,540.00 | Footnotes: F3
• Sold 280 shares of Stock Option (Right to Buy) at $15.8 per share (Derivative)
  Date: 2026-01-09 | Code: M | Expires: 2027-03-02 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
• F4: The shares underlying this stock option are fully vested and exercisable.